Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Jul 25.

Published in final edited form as: J Natl Compr Canc Netw. 2019 Jul 1;17(7):813–820. doi: 10.6004/jnccn.2018.7281

Table 3:

Imaging and Serum Tumor Biomarker Use During the Surveillance Period

	All Women n=2,923	Stage (0-IIa) n=2,561	Stage (IIb+) n=362
No Advanced Imaging Use	2443 (83.5%)	2207 (86.2%)	236 (65.2%)
Advanced Imaging Use^a	480 (16.5%)	354 (13.8%)	126 (34.8%)
Bone Scan	132 (4.5%)	94 (3.7%)	38 (10.5%)
CT	370 (12.7%)	266 (10.4%)	104 (28.7%)
PET – CT	85 (2.9%)	54 (2.1%)	31 (8.6%)
Serum tumor biomarker Use	930 (31.8%)	748 (29.2%)	182 (50.3%)

^(a)

Including any combination of Bone Scan, CT, or PET-CT and/or imaging